The OIS Index returned to four-digit territory in May, surpassing 1,000 for the first time since the index was launched in October 2016. The OIS Index was initially set to 1,000 on October 1, 2016, and over the ensuing ...
Ophthalmic Stocks’ Rally Rolls Through April
The OIS Index gained 5.2% in April, on the heels of a 4.4% gain in March. Ophthalmic stocks have far outperformed key market benchmarks over the past one and three months. The NASDAQ Biotechnology Index declined 3% ...
15 Things We Learned at OIS@ASCRS
Here are 15 takeaways from last week's OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision accommodating intraocular lens implanted. The average objective ...
Lurker Describes Next Steps for EyePoint
Within a week Nancy Lurker went from president and CEO of what had been known as an R&D company to the same title at a commercial specialty pharma company in the ophthalmology space, and she didn't even have to change ...
41 Things On Tap at OIS@ASCRS
There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 - including five different breakout sessions on everything from dry eye to emerging glaucoma therapies, the signature sessions on ...
OIS Index Outperforms Market in Another Volatile Month
The OIS Index gained 4.4% in March, far outperforming its key benchmarks during another volatile month for the markets. The NASDAQ Biotechnology Index declined by 1.3% in March, while the overall US stock market as ...
OIS Index Follows Market Downward During a Rocky February
The OIS Index declined by 4.2% in February, tracking stock market benchmarks during a volatile month. The NASDAQ Biotechnology Index suffered a slightly larger decline of 5.4%, while a composite of US medical device ...
OIS Index Delivers Small Gain, But Lags Benchmarks in January
In January, the OIS Index scratched out a small gain, but underperformed its relevant benchmarks. The OIS Index gained 0.3%, compared with gains of 7% for the NASDAQ Biotechnology Index, 10.2% for a composite of US ...
With Early Rhopressa ‘Present,’ Aerie Plots Next Steps
Aerie Pharmaceuticals’ CEO and chairman Vicente Anido Jr., PhD, says the company got “an early Christmas present” when the Food and Drug Administration approved Rhopressa – a once-daily eye drop for lowering elevated ...
Next for Spark: Working Out Payment Models
As the first drug company to get Food and Drug Administration Approval for a gene therapy to treat an inherited disease, Spark Therapeutics has also come in first in developing a payment model for a one-off treatment ...
OIS Index Declines Despite Positive Milestone Achievements
December was a month of positive milestones for key companies in the OIS Index. On December 18, more than two months before its February 28 Prescription Drug User Fee Act (PDUFA) date, Aerie Pharmaceuticals announced ...
What’s Moving Through the R&D Pipeline in 2018
Instead of looking at the year past, OIS Weekly is wrapping up 2017 by looking at the year ahead. Here’s a rundown of significant regulatory filings and actions along with trial readouts anticipated in 2018. This list is ...
- 1
- 2
- 3
- …
- 7
- Next Page »
